Imkeldi in Kuwait
Philadelphia-chromosome-positive CML in chronic phase (adults and pediatrics) and Ph+ ALL (pediatrics, in combination… · Hematology/oncology (Ph+ CML and Ph+ ALL)
Imkeldi - overview
Imkeldi (imatinib oral solution) is manufactured by Shorla Oncology and indicated for CML/GIST. It is an Oral liquid BCR-ABL tyrosine kinase inhibitor (80 mg/mL strawberry-flavored solution) approved by the US FDA in 2024 and may be accessible to patients in Kuwait through a Named Patient Program or personal-import pathway.
Access in Kuwait
Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.
How Reserve Meds coordinates access in Kuwait
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Kuwait-specific eligibility.
- Treating physician in Kuwait issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Imkeldi from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Kuwait.
Typical timeline for Kuwait
End-to-end, most requests are completed in 2-6 weeks. Kuwait's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Kuwait ask
- Is the pathway legal in Kuwait? Yes - it operates under Kuwait's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Kuwait able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.